🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

445 results for “SK” Clear

  1. Watchful waiting, RO7198457 (autogene cevumeran)

    BioNTech SE

    Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer

    phase 2 small molecule active

    1 trial

  2. X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza)

    Biogen

    Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.

    phase 2 small molecule active

    1 trial

  3. Zilebesiran

    Alnylam Netherlands B.V.

    High Cardiovascular Risk

    phase 2 small molecule completed

    1 trial

  4. [203Pb]VMT01

    Perspective Therapeutics

    Recurrent Melanoma (Skin)

    phase 2 small molecule active

    1 trial

  5. activated recombinant human factor VII

    Novo Nordisk A/S

    Acquired Bleeding Disorder

    phase 2 small molecule completed

    2 trials

  6. aspirin and atorvastatin

    United Therapeutics Europe Ltd

    Cardiovascular Risk Factor

    phase 2 small molecule active

    1 trial

  7. autologous skin fibroblasts

    United Therapeutics Europe Ltd

    Wounds and Injuries

    phase 2 mab active

    1 trial

  8. elritercept

    Takeda

    Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS).

    phase 2 small molecule active

    1 trial

  9. oritavancin

    Targanta Netherlands B.V.

    Staphylococcal Skin Infections

    phase 2 small molecule completed

    1 trial

  10. talampanel

    Teva Pharma GmbH

    Dyskinesias

    phase 2 small molecule completed

    1 trial

  11. telephone based skills training intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 other completed

    1 trial

  12. therapeutic autologous dendritic cells

    LISATA THERAPEUTICS, INC.

    Melanoma (Skin)

    phase 2 mab completed

    1 trial

  13. 15O-WATER, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, AZD3427, Dopamin Fresenius 50 mg/5 ml, Konzentrat zur Herstellung einer Infusionslösung, Placebo for AZD3427 or AZD3427 diluent

    AstraZeneca AB

    Heart failure with reduced ejection fraction, Renal impairment

    phase 1 small molecule active

    1 trial

  14. A Multicentre, Randomised Phase Ib Trial to evaluate Neoadjuvant Immunotherapy Combination of Nivolumab alone or plus Ipilimumab with the IL-2 Superkine MDNA11 alone or with Tocilizumab in Patients with High-Risk, Surgically Resectable Melanoma – NEO-CYT

    Fondazione Telethon ETS

    High-Risk, Surgically Resectable Melanoma

    phase 1 other active

    1 trial

  15. A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  16. A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations

    Hutchmed Europe B.V.

    - Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation

    phase 1 other active

    1 trial

  17. A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  18. A Phase 1 study of GSK5764227 in participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  19. A Phase 1, First-in-Human, Dose Escalation Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

    Janssen-Cilag International N.V.

    Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Types of Myelodysplastic Neoplasms

    phase 1 other active

    1 trial

  20. A Phase 1b Study of Neoadjuvant Xaluritamig in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer

    Amgen

    Newly diagnosed localized Intermediate or High‐Risk Prostate Cancer

    phase 1 other active

    1 trial

  21. A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  22. A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

    AbbVie Deutschland GmbH & Co. KG

    Myelodysplastic Syndromes (MDS)

    phase 1 other active

    1 trial

  23. A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, and Participants with Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD)

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  24. A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition

    Pfizer Australia Pty Ltd

    Older adults at risk of malnutrition

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources